CSL Keeps Bull Despite Expectation of Flat FY27 Profit

Dow Jones

Jul 24

2333 GMT - CSL keeps its bull at UBS despite analysts seeing little scope for profit growth in fiscal 2027. The analysts tell clients in a note that they don't think competitive conditions have improved in major markets since CSL cut its guidance for the most recent fiscal year ended June 30. They think this will inform a cautious approach to fiscal 2027 guidance, although they are hopeful that the Australian biopharma will have some new contract wins to report at next month's annual result announcement. UBS's current expectation is for a flat underlying profit in fiscal 2027. UBS has an unchanged buy rating on the stock and a target price of 158.00 Australian dollars. Shares are at A$115.75 ahead of the open. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

July 23, 2026 19:33 ET (23:33 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2653744837"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2653744837\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2653744837?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-24 07:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653744837","market":"fut","top_or_hot":-1,"title":"CSL Keeps Bull Despite Expectation of Flat FY27 Profit","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2333 GMT - CSL keeps its bull at UBS despite analysts seeing little scope for profit growth in fiscal 2027. The analysts tell clients in a note that they don't think competitive conditions have improved in major markets since CSL cut its guidance for the most recent fiscal year ended June 30. They think this will inform a cautious approach to fiscal 2027 guidance, although they are hopeful that the Australian biopharma will have some new contract wins to report at next month's annual result announcement. UBS's current expectation is for a flat underlying profit in fiscal 2027. UBS has an unchanged buy rating on the stock and a target price of 158.00 Australian dollars. Shares are at A$115.75 ahead of the open. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 23, 2026 19:33 ET (23:33 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSL Keeps Bull Despite Expectation of Flat FY27 Profit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSL Keeps Bull Despite Expectation of Flat FY27 Profit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-24 07:33</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2333 GMT - CSL keeps its bull at UBS despite analysts seeing little scope for profit growth in fiscal 2027. The analysts tell clients in a note that they don't think competitive conditions have improved in major markets since CSL cut its guidance for the most recent fiscal year ended June 30. They think this will inform a cautious approach to fiscal 2027 guidance, although they are hopeful that the Australian biopharma will have some new contract wins to report at next month's annual result announcement. UBS's current expectation is for a flat underlying profit in fiscal 2027. UBS has an unchanged buy rating on the stock and a target price of 158.00 Australian dollars. Shares are at A$115.75 ahead of the open. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 23, 2026 19:33 ET (23:33 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSL","symbol_name":"卡莱尔伙伴","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2653744837","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653744837","pubTimestamp":1784849580,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2333 GMT - CSL keeps its bull at UBS despite analysts seeing little scope for profit growth in fiscal 2027. The analysts tell clients in a note that they don't think competitive conditions have improved in major markets since CSL cut its guidance for the most recent fiscal year ended June 30. They think this will inform a cautious approach to fiscal 2027 guidance, although they are hopeful that the Australian biopharma will have some new contract wins to report at next month's annual result announcement. UBS's current expectation is for a flat underlying profit in fiscal 2027. UBS has an unchanged buy rating on the stock and a target price of 158.00 Australian dollars. Shares are at A$115.75 ahead of the open.  Dow Jones NewswiresJuly 23, 2026 19:33 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CSL":"卡莱尔伙伴"},"translate_title":"尽管预计 27 财年利润持平，CSL 仍保持牛市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL":1.5},"content_text":"2333 GMT - CSL keeps its bull at UBS despite analysts seeing little scope for profit growth in fiscal 2027. The analysts tell clients in a note that they don't think competitive conditions have improved in major markets since CSL cut its guidance for the most recent fiscal year ended June 30. They think this will inform a cautious approach to fiscal 2027 guidance, although they are hopeful that the Australian biopharma will have some new contract wins to report at next month's annual result announcement. UBS's current expectation is for a flat underlying profit in fiscal 2027. UBS has an unchanged buy rating on the stock and a target price of 158.00 Australian dollars. Shares are at A$115.75 ahead of the open. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 23, 2026 19:33 ET (23:33 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}